A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Conditions
Bladder Cancer · Urinary Bladder Neoplasms
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Michael G Oefelein Clinical Trials ( Site 0005), Bakersfield, California, United States
Carolina Urologic Research Center ( Site 0006), Myrtle Beach, South Carolina, United States
Medizinische Universität Wien ( Site 0021), Vienna, State of Vienna, Austria
UZ Gent ( Site 0031), Ghent, Oost-Vlaanderen, Belgium
CHU de Quebec - Hopital de l'Enfant-Jesus ( Site 0011), Québec, Quebec, Canada
Gustave Roussy ( Site 0041), Villejuif, Val-de-Marne, France
European Interbalkan Medical Center ( Site 0051), Thessaloniki, Greece
Rabin Medical Center ( Site 0062), Petah Tikva, Israel
Centro Ricerche Cliniche di Verona ( Site 0072), Verona, Veneto, Italy
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 0081), Amsterdam, North Holland, Netherlands
Akershus Universitetssykehus ( Site 0091), Lorenskog, Akershus, Norway
Hospital Universitario Virgen de la Victoria ( Site 0111), Málaga, Andalusia, Spain
Hospital Universitario 12 de Octubre ( Site 0112), Madrid, Madrid, Comunidad de, Spain
Ankara University Health Practice and Research Hospitals ( Site 0132), Ankara, Turkey (Türkiye)
Study leads
Medical Director
Study Director
Merck Sharp & Dohme LLC